ERBB2 and breast cancer: Consistent with these studies, Xi et al. also reported reduced vascularization in Hsf1+/− and Hsf1−/− Neu-driven mammary tumors compared to Hsf1+/+ Neu+ tumors, based upon CD31 staining [63].